AŞAysun Şeker

Aysun Şeker

*This is an algorithmically generated author record based on publicly available information.

Aysun Şeker has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative associations of waist circumference and body-mass index with reduced kidney function in patients with type 2 diabetes mellitus

    by Aysun Şeker

    Aims: Central obesity may better reflect metabolic risk than general obesity in adults with type 2 diabetes mellitus (T2DM). This study compared the associations of waist circumference (WC) and body-mass index (BMI) with reduced kidney function.Methods: This retrospective, cross-sectional study included 300 adults with T2DM. Demographic, anthropometric, clinical, and laboratory data were obtained from electronic medical records. Reduced kidney function was defined as an estimated glomerular filtration rate (eGFR)

  • Open Access

    Association between uric acid to HDL cholesterol ratio and HbA1c in type 2 diabetes mellitus: a novel biomarker of glycemic control

    by Aysun Şeker, Nurdan Şentürk Durmuş

    Objective: The uric acid–to–high-density lipoprotein cholesterol ratio (UHR) has emerged as a potential metabolic marker reflecting insulin resistance and metabolic imbalance. However, evidence regarding its association with glycemic control in type 2 diabetes mellitus (T2DM) remains limited. This study aimed to evaluate the relationship between UHR and glycemic control in patients with T2DM and to investigate whether this association differs by gender. Methods: This cross-sectional study included 216 participants, comprising 161 patients with T2DM and 55 healthy controls. Patients with T2DM were categorized as well-controlled (HbA1c < 7%) or poorly controlled (HbA1c ≥ 7%). UHR was calculated as the ratio of serum uric acid to HDL cholesterol. Group comparisons, correlation analyses, and hierarchical logistic regression models were performed. Analyses were adjusted for gender, age, body mass index (BMI), and estimated glomerular filtration rate (eGFR). Gender-stratified analyses were conducted to evaluate sex-specific associations. Results: UHR levels were significantly higher in patients with T2DM compared with controls ( p < 0.001). UHR showed significant positive correlations with HbA1c ( r = 0.288, p < 0.001) and fasting plasma glucose ( r = 0.332, p < 0.001). In hierarchical logistic regression analyses, UHR remained independently associated with poor glycemic control after full adjustment (OR = 1.297, 95% CI: 1.186–1.436, p < 0.001). Receiver operating characteristic analysis showed moderate discriminative performance of UHR for identifying poorly controlled diabetes (AUC = 0.762, 95% CI: 0.698–0.827, p < 0.001). In gender-stratified analyses, UHR was significantly higher in diabetic women ( p < 0.001) and diabetic men ( p = 0.002) compared with controls, whereas direct comparisons between sexes did not reveal a significant difference. Conclusion: UHR is independently associated with poor glycemic control in patients with T2DM, with consistent findings across both genders. As a simple and accessible biomarker reflecting metabolic imbalance, UHR may help identify patients at risk of inadequate glycemic control. Prospective studies are needed to clarify its predictive value in diabetes management.

  • Open Access

    Association between atherogenic index of plasma and MASLD in patients with type 2 diabetes: a cross-sectional study

    by Aysun Seker, Seydahmet Akın

    Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM). The atherogeni

  • Prevalence of Subclinical Hypothyroidism and Its Association with Noninvasive Fibrosis Scores in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

    by Aysun Şeker

    Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely related to obesity, insulin resistance, and diabetes mellitus. Thyroid hormones play a key role in lipid and glucose metabolism, and subclinical hypothyroidism has been suggested to contribute to metabolic disturbances. This study aimed to determine the prevalence of subclinical hypothyroidism in patients with MASLD and evaluate its association with noninvasive fibrosis scores. This retrospective cross-sectional study included 200 adult patients diagnosed with MASLD. Patients were classified as having subclinical hypothyroidism or euthyroid status based on thyroid function tests. Demographic characteristics, metabolic parameters, and laboratory findings were recorded. Fibrosis risk was assessed using the Fibrosis-4 (FIB-4) index and the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS). Group comparisons, correlation analyses, and multivariable logistic regression were performed. The mean age of the study population was 54.2 ± 9.7 years, 58% of patients were female, and the prevalence of subclinical hypothyroidism was 18%. No significant differences were observed between subclinical hypothyroid and euthyroid groups in FIB-4 or NFS values. A weak but statistically significant correlation was observed between TSH levels and the FIB-4 index (r = 0.15, p = 0.034), whereas no significant correlation was found with NFS. In multivariable analysis adjusted for age, sex, body mass index, diabetes mellitus, homeostasis model assessment of insulin resistance (HOMA-IR), and triglyceride-to-high-density lipoprotein (HDL) cholesterol ratio, subclinical hypothyroidism was not independently associated with advanced fibrosis risk. These findings indicate metabolic factors remain the primary determinants of fibrosis risk.

  • Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score and Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus

    by Aysun Şeker, Seydahmet Akin, Doğa Coşkun

    Background Diabetic neuropathy (DN) is a common microvascular complication of type 2 diabetes mellitus (T2DM), associated with chronic inflammation and metabolic dysregulation. The hemoglobin–albumin–lymphocyte–platelet (HALP) score is a composite index reflecting nutritional and inflammatory status, but its association with DN remains insufficiently characterized. Methods In this retrospective cross-sectional study, 212 patients with T2DM were evaluated. DN was defined using electrophysiological criteria. Multivariable logistic regression analysis was performed to assess the association between HALP and DN after adjustment for age, sex, diabetes duration, body mass index, and HbA1c. HALP was analyzed as a continuous variable (per 0.1-unit increase) and in quartiles. Receiver operating characteristic (ROC) curve analysis was used to evaluate model discrimination. Results Diabetic neuropathy was present in 45.2% of patients. HALP levels were significantly lower in patients with DN compared to those without DN (0.36 ± 0.18 vs. 0.72 ± 0.39, p < 0.001). In multivariable analysis, HALP remained independently associated with DN (OR per 0.1-unit increase: 0.46, 95% CI 0.35–0.58, p < 0.001). Quartile analysis showed a graded inverse association (p for trend < 0.001). The addition of HALP improved model discrimination compared to the base model (AUC 0.868 vs. 0.567). Conclusion HALP is inversely associated with diabetic neuropathy in patients with T2DM and may represent an integrated marker of metabolic and inflammatory burden.

  • Open Access

    Persistent hyperprocalcitoninemia as the initial diagnostic clue to sporadic medullary thyroid carcinoma

    by Aysun Şeker

    Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumour arising from parafollicular C cells, and serum calcitonin remains its most reliable biochemical marker. Procalcitonin (PCT), widely used in the evaluation of bacterial infections, is usually undetectable under non-infectious conditions. Persistent elevation of PCT in the absence of clinical or microbiological evidence of infection is uncommon and may represent an early clue to underlying endocrine malignancy. We report the case of a 48-year-old woman who presented with markedly elevated PCT levels (>20 ng/ml) detected during routine laboratory testing despite being asymptomatic and having normal inflammatory markers. Extensive infectious work-up was negative, and antibiotic therapy did not reduce PCT levels. Further endocrine evaluation revealed a calcitonin level >2000 ng/l, elevated carcinoembryonic antigen, and a suspicious thyroid nodule on ultrasonography. Fine-needle aspiration with calcitonin washout confirmed the diagnosis of MTC. The patient underwent total thyroidectomy with central neck dissection, and histopathology demonstrated a 4.5 cm sporadic MTC without nodal metastasis. Postoperative PCT and calcitonin levels declined markedly, supporting their parallel behaviour in relation to disease activity. This case highlights the clinical importance of considering MTC in patients with unexplained hyperprocalcitoninemia and supports the potential role of PCT as an adjunct biomarker in diagnostic evaluation and postoperative monitoring once infection has been excluded.


  • Open Access

    Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia

    by Aysun Seker, Nurdan Senturk Durmus

    Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including potentially life-threatening electrolyte imbalances such as hypocalcemia and hypophosphatemia. Developing monitoring strategies for electrolyte abnormalities can be facilitated by the increased awareness of this interaction. We present the case of a 62-year-old female patient who developed severe, symptomatic hypocalcemia and hypophosphatemia despite having normal renal function. These abnormalities occurred concomitantly during treatment with denosumab for osteoporosis and ferric carboxymaltose for iron deficiency anemia.


  • Open Access

    Bone mineral density in patients with Cushing’s syndrome

    by Aysun Seker, Dilek Gogas Yavuz

    Objective: Cushing’s syndrome is caused by the excessive secretion of cortisol or the intake of exogenous cortisol. Morbidity caused by osteoporosis is a major complication that cannot be ignored. We conducted a study to evaluate bone density and fracture risk factors in patients with Cushing’s syndrome. Patients and Methods: This retrospective case-control study involved 176 patients diagnosed with Cushing’s syndrome [153 female and 34 male patients] and 84 controls [72 female and 12 male patients]. Patients admitted to the clinics within the last eight years were included in the analysis. We collected demographic, clinic laboratory data, and bone densitometry measurements from electronic patient files. The classification of patients into normal, osteopenia, or osteoporosis groups is determined by their Body Mineral Density measurements based on the World Health Organization criteria. Results: Among the patients, 135 were diagnosed with Cushing’s disease and 41 with adrenal adenomas. Patients with Cushing’ syndrome showed a higher incidence of osteopenia (11.4%) and osteoporosis (2.8%) when compared to the control group. No osteoporosis cases were found in the control group, while nine cases of osteopenia were detected. Osteopenia was significantly more common in adrenal adenoma patients than in those with pituitary Cushing’s disease. Osteopenia was present in 39.1% of adrenal Cushing’s patients, with only 8.7% (n = 2) having osteoporosis. Osteopenia was observed in 11 patients (23.4%) with pituitary Cushing’s disease, while only 4 patients (8.5%) had osteoporosis. Conclusions: Osteopenia is more prevalent in patients with adrenal Cushing’s syndrome.